Recombinant Human CPLX2 protein(Asp2-Lys134), His-tagged

• Cat.No.: CPLX2-3941H
• Product Overview: Recombinant Human CPLX2 (Q6PUV4-1) (Asp 2-Lys 134) was expressed in E. coli, with a polyhistide tag at the N-terminus.

Specification

• Species: Human
• Source: E.coli
• Tag: His
• Protein Length: 2-134 a.a.
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human CPLX2 consists of 144 amino acids and has a calculated molecular mass of 16.8 kDa. It migrates as an 21 kDa band in SDS-PAGE under reducing conditions.
• Purity: > 90 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CPLX2 complexin 2 [ Homo sapiens ]
• Official Symbol: CPLX2
• Synonyms: CPLX2; complexin 2; complexin-2; CPX 2; DKFZp547D155; CPX II; synaphin 1; synaphin-1; complexin II; CPX2; Hfb1; 921-L; CPX-2; MGC138492
• Gene ID: 10814
• mRNA Refseq: NM_001008220
• Protein Refseq: NP_001008221
• MIM: 605033
• UniProt ID: Q6PUV4

Case Study

Case 1: Tsuru E, et al. Immun Inflamm Dis. 2019

Initially found in neurons, Complexins (CPLXs) help regulate vesicle fusion with cell membranes. While CPLX function in neurons is understood, their role in immune cells isn't clear. In our study, CPLX2 was seen in B cells but not T cells. Researchers explored this using CPLX2 knockout (KO) mice. We found that IgM, mostly natural antibodies, was higher in KO mice than in wild-types, though other antibodies stayed the same. Also, CPLX2 KO mice showed more IgM and IgG1 secretion from spleen cells, highlighting CPLX2's role in B cell function.

Fig1. Western blot analyses show protein expression levels of CPLX2, SNAP23, and SNAP25 in T and B cells.

Fig2. Concentrations of serum immunoglobulin G (IgG), IgA, and IgE in WT and CPLX2 KO mice were measured by ELISA.

Case 2: Raevskaya NM, et al. Gene. 2005

This study dives into the organization of the human complexin 2 (CPLX2) gene, which makes a 134-amino-acid protein. Located on chromosome 5q35.3, CPLX2 stretches over 87 kb and includes five exons. We discovered an alternate gene transcript variant with a changed 5' UTR but the same coding sequence. This variant lacks exons I and II, replacing them with exon A from intron 2. Using RT-PCR, we found both transcript types in human brain mRNA. The findings suggest two TATA-less promoters manage these transcripts, with expression varying across brain regions. This gene's structure is conserved in humans and rodents.

Fig1. Products specific to CPLX2_v2 (lane 1, primers F7/R6, lane 2, primers F8/R7).

Fig2. Low-resolution electrophoresis of human CPLX2 gene transcription start sites.

Application

Recombinant CPLX2 protein is gaining attention for its potential role in neuroscience and cancer diagnostics. In the brain, CPLX2 is involved in synaptic function, helping regulate neurotransmitter release. This makes it a promising target for research into neurological disorders like Alzheimer's or epilepsy, where synaptic dysfunction plays a key role. By understanding and manipulating CPLX2, scientists hope to develop therapies that improve synaptic function and offer relief for patients with these challenging conditions. In cancer diagnostics, CPLX2 shows potential as a biomarker for certain types of tumors, such as high-grade lung neuroendocrine tumors (LNETs). Its distinct expression patterns can help distinguish between cancer types, guiding treatment decisions and improving outcomes. By using CPLX2 as a diagnostic tool, doctors could more accurately predict disease progression and tailor therapies to the individual, leading to more personalized and effective cancer care. This dual potential in both brain health and cancer treatment underscores CPLX2's value in advancing medical science.